<DOC>
	<DOCNO>NCT00073736</DOCNO>
	<brief_summary>Hepatocellular carcinoma ( HCC ) common primary cancer liver . MB07133 develop treatment inoperable HCC , use platform technology know HepDirectTM , enable drug target specifically liver . The objective study determine safety tolerability MB07133 .</brief_summary>
	<brief_title>Safety Tolerability I.V . Infusion MB07133 Patients With Unresectable Hepatocellular Carcinoma</brief_title>
	<detailed_description>To determine maximum tolerate dose MB07133 administer 7-day continuous i.v . To characterize safety profile pharmacokinetics MB07133 metabolites continuous infusion . To determine effect MB07133 hepatocellular carcinoma ( HCC ) tumor size .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Patients diagnosis local unresectable HCC confirm histology use fine needle aspirate ( FNA ) liver biopsy . `` Local '' define disease either restrict liver contiguous liver identifiable extrahepatic disease . Patients ChildPugh Class A liver function . For purpose trial , eligible patient must Encephalopathy Ascites total ChildPugh score great 6 baseline Males females 18 year age old Ability provide write informed consent initiation studyrelated procedure ability , opinion Principal Investigator , comply requirement study Male female subject surgically sterile , remain abstinent , agree practice double barrier form birth control screen 30 day ( female ) 90 day ( male ) , last dose study medication History presence clinically significant acute unstable cardiovascular , cerebrovascular ( stroke ) , renal , GI , pulmonary , immunological ( exception presence hepatitis B virus [ HBV ] , HCV hepatitis , cirrhosis ) , endocrine , central nervous system disorder Patient history cancer hepatocellular ( exclude resect basal cell carcinoma ; curatively resect stage 1 less cervical cancer disease free 5 year ) . Patients distant metastasis extrahepatic disease An Eastern Cooperative Oncology Group ( ECOG ) performance status score great equal 2 Current encephalopathy current treatment encephalopathy History drug alcohol abuse within 6 month screen History , current clinically significant mental disorder antagonistic personality compromise validity inform consent A document variceal hemorrhage within 4 month screen Neutrophil count less equal 1,500/mm3 , platelet count less equal 100,000/mm3 , hemoglobin le equal 8.5 g/dL , Prothrombin Time ( INR ) great 1.3 ( vitamin K supplementation allow ) Serum creatinine great 1.1 time upper limit normal History human immunodeficiency virus acquire immune deficiency syndrome Use investigational drug product participation drug study within 30 day dose Liver function define : serum bilirubin great 1.5 time upper limit normal aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) great 5 time upper limit normal , serum albumin le 3.2 g/dL History gout abnormal uric acid metabolism The clinical presence ascites Treatment HCC within 30 day screen chemotherapy treatment target lesion ( ) chemoembolization , PEI , surgery Radiofrequency ( `` RF '' ) ablation target lesion ( ) within 60 day screen Subjects life expectancy le 12 week Subjects receive organ transplant Subjects currently receive coumadin heparin Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Hepatocellular</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Liver</keyword>
	<keyword>Cancer</keyword>
</DOC>